--- title: "Xencor (XNCR) stock listing, news and investor profile" url: "https://aibio.space/companies/xencor/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Xencor, Inc. (NASDAQ: XNCR), United States. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- XNCR Xencor, Inc. NASDAQ · United States # Xencor (XNCR) news Listings · 2026-06-18 ## [Xencor holders approve 4,000,000-share increase to 2023 equity plan](https://aibio.space/news/xencor-holders-approve-4-000-000-share-increase-2023-equity-plan/) The annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor. ## Latest Xencor news 1. 2026-03-09 Distress [Genentech to end Xencor collaboration and license agreement September 4, 2026](https://aibio.space/news/genentech-end-xencor-collaboration-license-agreement-september-4-2026/) Genentech elected to terminate the agreement for convenience. Xencor says it expected the move. 2. 2025-02-13 Distress [Xencor says 2023 and 2024 interim financials can't be relied on, will restate royalty as debt](https://aibio.space/news/xencor-says-2023-2024-interim-financials-cant-relied-will-restate/) Xencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected. ## Xencor at a glance - **Ticker**: XNCR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $44.7 million ### Related companies - [Vor Biopharma](https://aibio.space/companies/vor-biopharma/) NASDAQ: VOR - [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) OTC: GSTC - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) NASDAQ: BMRN - [MindWalk Holdings](https://aibio.space/companies/mindwalk/) NASDAQ: HYFT - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) OTC: MCET - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) NASDAQ: ALMR - [Aditxt](https://aibio.space/companies/aditxt/) OTC: ADTX - [Provectus Biopharmaceuticals](https://aibio.space/companies/provectus-biopharmaceuticals/) OTC: PVCT ### Also on NASDAQ - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) ALZN - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) CVKD - [Harrow](https://aibio.space/companies/harrow/) HROW - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) PVLA - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) PRQR ## Xencor annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$125.6 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | [$110.5 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | | Research and development | [$239.4 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | [$227.7 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | | Net income (loss) | [-$91.9 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | [-$232.6 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | | Cash from operations | [-$135.1 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | [-$202.2 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | | Cash and equivalents | [$54.1 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000056/) | [$40.9 million](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $44.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Xencor What is the ticker symbol of Xencor? Xencor, Inc. trades under the ticker XNCR on NASDAQ. Where is Xencor listed? Xencor, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:XE9; LS:A1W96L; LSX:A1W96L. What is the SEC CIK of Xencor? The SEC Central Index Key (CIK) for Xencor, Inc. is 1326732. Its filings are on SEC EDGAR. How many shares does Xencor have outstanding? 74,353,397 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Xencor listed under? Our directory records Xencor, Inc. under United States. What does Xencor do? Our directory classifies Xencor, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Xencor? The ISIN recorded for Xencor, Inc. is US98401F1057. Does aibio.space cover Xencor? aibio.space lists Xencor, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Xencor incorporated? SEC records list its state or country of incorporation as DE. What was Xencor's revenue last year? $125.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Xencor profitable? Xencor, Inc. reported a net loss of $91.9 million for the fiscal year ended Dec 31, 2025, and used $135.1 million of cash in operations, per its annual report to the SEC. How much does Xencor spend on research and development? $239.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Xencor have? $44.7 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Xencor (XNCR) stock news? Our latest story on Xencor, dated Jun 18, 2026: "Xencor holders approve 4,000,000-share increase to 2023 equity plan". The annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor. [Source](https://aibio.space/news/xencor-holders-approve-4-000-000-share-increase-2023-equity-plan/). Is Xencor in financial distress? Our latest distress story, dated Mar 9, 2026: "Genentech to end Xencor collaboration and license agreement September 4, 2026". Genentech elected to terminate the agreement for convenience. Xencor says it expected the move. [Source](https://aibio.space/news/genentech-end-xencor-collaboration-license-agreement-september-4-2026/). ## Investor discussion: Xencor Members talk about Xencor (XNCR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Xencor, newest first. Each line links the filing it comes from. 1. 2026-06-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000045/xncr-20260616.htm) 2. 2026-03-09 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/xncr-20260304.htm) 3. 2025-06-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000057/xncr-20250612.htm) 4. 2025-03-05 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000032/xncr-20250227.htm) 5. 2025-02-13 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000005/xncr-20250207.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:XNCR on TradingView](https://www.tradingview.com/symbols/NASDAQ-XNCR/). ## SEC filings and registration - **SEC name**: Xencor Inc - **CIK**: 1326732 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: XNCR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 465 N. HALSTEAD ST., PASADENA, CA, 91107 - **Phone**: 626-305-5900 - **Shares outstanding**: 74,353,397 as of 2026-07-31 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000056/xncr-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000049/xncr-20260729.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000045/xncr-20260616.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000043/xncr-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000042/xncr-20260506.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/xncr-20260504.htm) filed 2026-05-05 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000031/xncr-20260427.htm) filed 2026-04-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001326732), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Xencor, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XNCR, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Xencor, Inc. - **Ticker**: XNCR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US98401F1057 - **Other listed symbols**: GETTEX:XE9; LS:A1W96L; LSX:A1W96L - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-XNCR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/xencor/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Xencor (XNCR) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/xencor/